Fischer Biosciences

Fischer BioSciences is a private biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company specializes in the ubiquitin-proteasome system, specifically targeting deubiquitinating enzymes (DUBs) associated with the 19S regulatory particle, such as USP14 and UCHL5. Their research aims to overcome resistance to first-generation proteasome inhibitors in hematologic malignancies like multiple myeloma. By inhibiting these specific DUBs, Fischer BioSciences seeks to induce proteotoxic stress and apoptosis in malignant cells while sparing healthy tissue. The company operates primarily in the pre-clinical stage, advancing a pipeline of selective inhibitors for various oncology indications.